Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands, except share and per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Collaboration revenue — related party | $1,154 | $1,115 | $2,010 | $2,569 |
| Operating expenses: | ||||
| Research and development | 33,397 | 41,375 | 67,502 | 81,937 |
| General and administrative | 11,042 | 13,117 | 28,447 | 26,401 |
| Total operating expenses | 44,439 | 54,492 | 95,949 | 108,338 |
| Loss from operations | (43,285) | (53,377) | (93,939) | (105,769) |
| Other income: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's R&D?
- Prime Medicine (PRME) reported R&D of $33.4M in Q2 2026.
- How has Prime Medicine's R&D changed year-over-year?
- Prime Medicine's R&D decreased by 19.3% year-over-year, from $41.38M to $33.4M.
- What is the long-term trend for Prime Medicine's R&D?
- Over 3 years (2022 to 2025), Prime Medicine's R&D has grown at a 22.8% compound annual growth rate (CAGR), from $86.73M to $160.64M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Prime Medicine's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude